secwatch.observer — SEC 8-K summary
======================================

Issuer:     CORCEPT THERAPEUTICS INC (CORT)
CIK:        0001088856
Form:       8-K
Filed at:   2024-07-29T23:59:59+00:00
Accession:  0001628280-24-033281
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Corcept Q2 revenue up 39% to $163.8M; raises 2024 guidance to $640-670M
-----------------------------------------------------------------------

- Q2 revenue $163.8M, up 39% YoY; diluted EPS $0.32 vs $0.25.
- 2024 revenue guidance raised to $640-670M from $620-650M.
- Cash and investments $492.5M at June 30, up from $451M at March 31.
- NDA submission for relacorilant in Cushing's syndrome expected Q4; late-stage trial results (ROSELLA, GRADIENT, DAZALS) due by year-end.
- Record number of new Korlym prescribers and patients; hypercortisolism screening expanding.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1088856/000162828024033281/0001628280-24-033281-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1088856/000162828024033281/cort-20240729.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-033281

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer